<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842149</url>
  </required_header>
  <id_info>
    <org_study_id>H-20068527</org_study_id>
    <nct_id>NCT04842149</nct_id>
  </id_info>
  <brief_title>The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease</brief_title>
  <official_title>The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease: a Double-blind, Randomized, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chr Hansen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195&#xD;
      (Bif195) will result in improvement in clinical outcome in patients with small intestinal&#xD;
      Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with an incidence rate at&#xD;
      11/100 000 per year in Denmark.&#xD;
&#xD;
      The disease can potentially affect the entire gastrointestinal tract, though the most common&#xD;
      affected area is terminal ileum and the adjacent part of colon.&#xD;
&#xD;
      CD is a result of both genetic and environmental factors together with the intestinal&#xD;
      microbiota, however the precise etiology is unclear.&#xD;
&#xD;
      A change of the intestinal microbiota with a reduced occurrence of e.g. Bacteroides species,&#xD;
      Firmicutes and the anti-inflammatory bacteria Faecalibacterium prausnitzii is found in CD&#xD;
      patients compared to healthy controls. Also a reduction of the mucosa-associated&#xD;
      Bifidobacteria has been associated with the risk of mucosal inflammation.&#xD;
&#xD;
      The hypothesis that an imbalance between potentially beneficial and pathogenic bacteria&#xD;
      contribute to the pathogenesis of IBD, including CD, has led to the suggestion that&#xD;
      manipulation of the microbiota may be an attractive target for therapeutic interventions in&#xD;
      IBD.&#xD;
&#xD;
      A new probiotic bacterium, Bifidobacterium breve Bif195 (Bif195) has been identified and has&#xD;
      shown great effects on preventing enteropathy and ulcers on the gut mucosa in healthy&#xD;
      volunteers given acetylsalicylic acid (13), and thereby Bif195 has also shown a potential in&#xD;
      reducing gut permeability defects. This bacterium has not yet been investigated in CD&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bowel Wall Thickness (BWT) from baseline measured by intestinal ultrasound (IUS) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>IUS will be performed in the non-fasting patient lying in supine position with a high-end ultrasound machine (Siemens Sequoia) with 10L4 transducer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fecal calprotectin level from baseline at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>measured from a fecal sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in severity of symptoms from baseline measured by Harvey-Bradshaw index (HBI) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>HBI is a disease activity index for Crohns disease and consists of clinical parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life from baseline measured by Inflammatory Bowel Disease Questionnaire (IBDQ) Questionnaire Scores at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>The IBDQ is a widely used instrument to assess QoL among IBD patients and consists of 32 questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline on Color Doppler Imaging Score (0-3) including inflammatory fat and ulceration (yes/no) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>measured by intestinal ultrasound (IUS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse and severe adverse events</measure>
    <time_frame>16 weeks</time_frame>
    <description>Registered, if any events. Reported according to IHC-GCP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Bif195 capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The capsule will contain approximately 15*10^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bif195 capsules</intervention_name>
    <description>1 capsule daily for 8 weeks</description>
    <arm_group_label>Bif195 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>1 capsule daily for 8 weeks</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with small intestinal CD&#xD;
&#xD;
          -  Fecal calprotectin ≥ 250 ug/g&#xD;
&#xD;
          -  IUS evidence of small bowel inflammation with wall thickness ≥ 4 mm&#xD;
&#xD;
          -  At least 3 months af stable medical treatment&#xD;
&#xD;
          -  Able to read and speak Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive rectal swab for pathogenic microorganisms&#xD;
&#xD;
          -  Use of antibiotics, probiotics and systemic glucocorticosteroids within 4 weeks prior&#xD;
             to inclusion&#xD;
&#xD;
          -  Participation in other clinical trials within 30 days prior to inclusion&#xD;
&#xD;
          -  Pregnancy, planned pregnancy or breast feeding&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas M Petersen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastrounit, Copenhagen University Hospital Hvidovre, Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ida MB Grønbæk, MD</last_name>
    <phone>004530366773</phone>
    <email>ida.marie.bruun.groenbaek@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas M Petersen, MD, PhD</last_name>
    <phone>004538626199</phone>
    <email>andreas.munk.petersen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gastrounit, Copenhagen University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <state>Copenhagen</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas M Petersen, MD, ph.d</last_name>
      <phone>004538625960</phone>
      <email>andreas.munk.petersen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ida M Grønbæk, MD</last_name>
      <phone>+4538623862</phone>
      <email>andreas.munk.petersen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas M Petersen, MD, ph.d.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Andreas Munk Petersen</investigator_full_name>
    <investigator_title>Principal Investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

